

ATHERSYS, INC / NEW  
Form 8-K  
January 29, 2015

**UNITED STATES**  
**SECURITIES AND EXCHANGE COMMISSION**  
**WASHINGTON, DC 20549**

**FORM 8-K**

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d)**

**of the Securities Exchange Act of 1934**

**Date of report (Date of earliest event reported): January 27, 2015**

**ATHERSYS, INC.**

**(Exact Name of Registrant as Specified in Charter)**

**Delaware**  
**(State or Other Jurisdiction**

**of Incorporation)**

**001-33876**  
**(Commission**

**File Number)**

**20-4864095**  
**(IRS Employer**

**Identification No.)**

**3201 Carnegie Avenue,**

**Cleveland, Ohio**  
**(Address of Principal Executive Offices)**

**44115-2634**  
**(Zip Code)**

**Registrant's telephone number, including area code: (216) 431-9900**

**Not Applicable**

**(Former Name or Former Address, if Changed Since Last Report)**

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- .. Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- .. Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- .. Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- .. Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

---

**Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers**

On January 27, 2015, the Board of Directors of Athersys, Inc. (the *Company*), upon the recommendation of the Compensation Committee (the *Committee*) of the Board of Directors of the Company (the *Board*), approved the following cash bonuses to the named executive officers of the Company, based on individual performance and achievement of corporate goals in 2014:

| <b>Name</b>          | <b>Title</b>  | <b>Award</b> |
|----------------------|---|--------------|
| Dr. Gil Van Bokkelen | Chief Executive Officer                               | \$ 133,000   |
| William Lehmann, Jr. | President and Chief Operating Officer                 | \$ 82,500    |
| Dr. John Harrington  | Executive Vice President and Chief Scientific Officer | \$ 82,000    |
| Dr. Robert Deans     | Executive Vice President, Regenerative Medicine       | \$ 55,000    |
| Laura Campbell       | Vice President of Finance                             | \$ 36,000    |

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

**ATHERSYS, INC.**

By: /s/ Laura K. Campbell  
Name: Laura K. Campbell  
Title: Vice President of Finance

Date: January 29, 2015